Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 4/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27560040 | 1.00 | LPAR1 (0.56) | LPAR1MMELTA4HMAPTANPEP | |
| SCHEMBL6897939 | 0.87 | LPAR1 (0.54) | LPAR1MMEACE | |
| SCHEMBL27538262 | 0.86 | LPAR1 (0.53) | LPAR1MMEACE | |
| SCHEMBL6895388 | 0.86 | LPAR1 (0.53) | LPAR1MMEACE | |
| SCHEMBL6891317 | 0.86 | LPAR1 (0.53) | LPAR1MMEACE | |
| SCHEMBL6898194 | 0.85 | LPAR1 (0.43) | LPAR1MMEACEFOLH1 | |
| SCHEMBL27559953 | 0.85 | LPAR1 (0.43) | LPAR1MMEACEFOLH1 | |
| SCHEMBL6896205 | 0.84 | LPAR1 (0.53) | LPAR1MMELTA4HANPEPACE | |
| SCHEMBL6890154 | 0.84 | LPAR1 (0.53) | LPAR1MMELTA4HANPEPACE | |
| SCHEMBL6896882 | 0.83 | HSD17B10 (0.46) | LPAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | LPAR1 4229/4885MME 1516/4885LTA4H 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.